Rivastigmine Teva

RSS

rivastigmine

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Rivastigmine Teva has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 27/09/2012

Authorisation details

Product details
Name
Rivastigmine Teva
Agency product number
EMEA/H/C/001044
Active substance
rivastigmine
International non-proprietary name (INN) or common name
rivastigmine
Therapeutic area (MeSH)
  • Dementia
  • Alzheimer Disease
  • Parkinson Disease
Anatomical therapeutic chemical (ATC) code
N06DA03
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Teva Pharma B.V.
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
17/04/2009
Contact address
Computerweg 10
NL-3542 DR Utrecht
The Netherlands

Product information

10/09/2012 Rivastigmine Teva - EMEA/H/C/001044 - IB/0008/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Anticholinesterases

Therapeutic indication

Symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

Assessment history

How useful was this page?

Add your rating